cardiology-summit-2019-keynote

5 / 6

Cardiology Summit 2019 Journal of Cardiovascular Medicine and Therapeutics | Volume 3
Page 36
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
March 25-26, 2019 | Amsterdam, Netherlands
CARDIOLOGY
AND CARDIAC NURSING
3rd World Congress on
PREDICTION OF THE POPULATION
AT RISK OF ATHEROTHROMBOTIC
DIDSEASE-2018 UPDATE (BACK TO
FRAMINGHAM)
The Framingham Study has shown that the population at risk of Athero-
Thrombotic Disease (ATD) differs from those not at risk by a number of con-
ditions termed risk factors and differs not in kind but in severity of those risk
factors. The chief risk factors are cigarette smoking, dyslipidemia, and hyperten-
sion. Dyslipidemia is measured by the Cholesterol Retention Fraction (CRF, de-
fined as [LDL-HDL]/LDL). Hypertension is determined by systolic blood pressure
(SBP). CRF-SBP plot positions are know for 870 people who developed some
form of clinical ATD during the 1978-2018 timeframe. When the CRF-SBP plots
of these 870 patients are plotted on a graph, a threshold line can be drawn with
CRF-SBP plot loci of (0.74,100) and (0.49,140) when the precipitation method of
HDL-cholesterol measurement is used. Above this threshold line lie the plots
of 85% of all ATD patients of any age. If cigarette smoking status is accounted
for, then only 6% of ATD patients can not be predicted by CRF-SBP plot position
above the threshold line and/or cigarette smoking status. These plots may be
stratified into CRF-SBP cohorts and the average age of ATD onset calculated.
Current cigarette smoking is associated with early onset ATD (aged 64 years or
less) in virtually all cohorts; past cigarette smoking, with cohorts having CRF val-
ues of 0.70 or higher; never smoking, with cohorts having CRF values of 0.75 or
higher. The population at risk of ATD can be identified and the average age of
ATD onset predicted.
William E Feeman Jr, J Cardiovasc Med Ther 2019, Volume 3
William E Feeman Jr is a family physician who
trained at the Ohio State University College
of Medicine and has spent his professional
career investigating the primary and second-
ary prevention of Athero Thrombotic Disease
(ATD). His database includes 870 patients
who developed some form of clinical ATD in
the 1978-2018 timeframe. He has published
his results in major medical journals and has
done multiple poster presentations in re-
gional/national/international symposia.
William E Feeman Jr
The Bowling Green Study, USA
BIOGRAPHY